Candage Raymond, Jones Keith, Luchette Fred A, Sinacore James M, Vandevender Darl, Reed R Lawrence
Divisions of General Surgery and Plastic Surgery, Department of Surgery, Stritch School of Medicine, Loyola University Medical Center, Maywood, IL 60153, USA.
Surgery. 2008 Oct;144(4):703-9; discussion 709-11. doi: 10.1016/j.surg.2008.06.018. Epub 2008 Aug 29.
Surgeons continue to search for the ideal prosthetic material to repair complex abdominal wall hernias. Recently, a new biologic material was introduced into the surgeon's arsenal. The purpose of this study is to review a single institution's experience with the use of human acellular dermal matrix (HADM [AlloDerm]) for repair of hernias.
This was a retrospective review of all patients who received HADM for repair of an abdominal wall hernia. Patient demographics, comorbidities, wound contamination, operative technique, complications, and hernia recurrence were analyzed.
Between May 2004 and October 2007, HADM was implanted in a total of 46 patients undergoing repair of a ventral hernia. The average age was 54 years (range, 26-77), with an average American Society of Anesthesiologists classification of 2.5 (range, 1-4). Indications for use of HADM included complex ventral hernia repair (n = 34), mesh infection/enterocutaneous fistula (n = 10), and peritonitis (n = 2). The incidences of comorbidities were hypertension in 47%, diabetes mellitus in 16%, and coronary artery disease in 11%. The majority (87%; n = 40) of the procedures were performed on an elective basis. Seventeen procedures were performed in contaminated wounds. The HADM was placed as reinforcement to the hernia repair in 26 patients and as a "bridge" between the fascial edges in 20 patients. The average follow-up was 12.1 months. Wound complications were frequent at 54%. There were 6 recurrent hernias and 8 patients with eventration of the bioprosthesis so that the recurrent hernia rate was 30%. None of the recurrences were associated with a postoperative wound infection. The majority (88%) of patients who developed eventration of the HADM had a repair using the bioprosthesis to "bridge" an abdominal wall defect. Hernia recurrence and eventration were not associated with use of HADM in a contaminated/infected wound.
HADM is a suitable prosthesis for repair of complex and routine abdominal wall defects. This bioprosthesis can incorporate into contaminated tissue without becoming infected. Eventration occurs when HADM is utilized as a fascial replacement rather than as a reinforcement.
外科医生一直在寻找用于修复复杂腹壁疝的理想假体材料。最近,一种新型生物材料被引入外科医生的工具库。本研究的目的是回顾单一机构使用人脱细胞真皮基质(HADM [AlloDerm])修复疝的经验。
这是一项对所有接受HADM修复腹壁疝患者的回顾性研究。分析了患者的人口统计学特征、合并症、伤口污染情况、手术技术、并发症和疝复发情况。
在2004年5月至2007年10月期间,共有46例接受腹侧疝修复的患者植入了HADM。平均年龄为54岁(范围26 - 77岁),美国麻醉医师协会平均分级为2.5(范围1 - 4)。使用HADM的指征包括复杂腹侧疝修复(n = 34)、补片感染/肠皮肤瘘(n = 10)和腹膜炎(n = 2)。合并症的发生率为高血压47%、糖尿病16%、冠状动脉疾病11%。大多数手术(87%;n = 40)为择期手术。17例手术在污染伤口进行。26例患者将HADM作为疝修复的加强材料放置,20例患者将其作为筋膜边缘之间的“桥梁”。平均随访时间为12.1个月。伤口并发症发生率较高,为54%。有6例复发性疝,8例生物假体膨出,因此复发疝率为30%。所有复发均与术后伤口感染无关。发生HADM膨出的患者中,大多数(88%)使用生物假体“桥接”腹壁缺损进行修复。疝复发和膨出与在污染/感染伤口中使用HADM无关。
HADM是修复复杂和常规腹壁缺损的合适假体。这种生物假体可融入污染组织而不被感染。当HADM用作筋膜替代物而非加强材料时会发生膨出。